See the DrugPatentWatch profile for kesimpta
How Is Kesimpta Administered?
Kesimpta (ofatumumab) is self-administered at home via a prefilled Sensoready pen for subcutaneous injection. The standard loading dose is 300 mg (two 150 mg injections) on day 1, then 300 mg one week later, and 300 mg two weeks after that. Maintenance is a single 300 mg subcutaneous injection once monthly.[1]
How Is Ocrevus Administered?
Ocrevus (ocrelizumab) requires intravenous (IV) infusion in a healthcare setting. Initial dosing is two 300 mg infusions two weeks apart (600 mg total), each lasting about 2.5 hours initially (shorter with subsequent doses). Maintenance is 600 mg every six months, with infusions taking 3.5-5 hours initially, reducible to 2 hours after the first two.[2]
Is Kesimpta Easier to Administer?
Yes, Kesimpta is easier for patients due to self-administration at home, no need for clinic visits or IV lines, and shorter monthly procedure time (under 10 minutes per dose). Ocrevus demands travel to an infusion center every six months for hours-long supervised infusions, increasing logistical burden.[1][2]
What Do Patients Say About the Difference?
Patient forums and reviews highlight Kesimpta's convenience—no infusion reactions during self-injection for most, flexibility in scheduling, and less disruption to daily life. Ocrevus users often report fatigue from long infusions and center wait times, though some prefer it for monitored safety.[3]
How Do Dosing Schedules Compare?
Kesimpta: Monthly subcutaneous shots after loading.
Ocrevus: Every six months IV, but higher volume per session.
Kesimpta's frequency suits those avoiding rare clinic trips; Ocrevus reduces visits but extends each one.[1][2]
Any Risks or Training Needs?
Kesimpta requires initial healthcare demo and training for self-injection; injection-site reactions occur in ~20%. Ocrevus carries higher infusion reaction risk (35-50% first dose), needing premeds and monitoring. Home use trades supervision for convenience.[1][2]
[1]: Kesimpta Prescribing Information (Novartis)
[2]: Ocrevus Prescribing Information (Genentech)
[3]: Patient reviews aggregated from Drugs.com and MultipleSclerosis.net (accessed 2023)